11C-ZTP-1 Imaging for Healthy Subjects

This trial tests a new tracer called 11C-ZTP-1, which helps researchers measure a protein linked to inflammation and brain signaling. The goal is to determine if this tracer can provide clear images of the brain and body using advanced scanning methods. It is designed for healthy individuals who have already been screened under specific criteria. Participants will undergo imaging scans, such as PET/CT scans, to assess the tracer's effectiveness. As a Phase 1 trial, this research focuses on understanding how the tracer functions in people, offering participants the opportunity to be among the first to receive it.

Yes, you may need to stop taking certain medications. The trial excludes participants taking CYP3A4 inhibitors (like grapefruit juice or certain antibiotics) and CYP3A4 inducers (like St. John's Wort).

Research has shown that the tracer 11C-ZTP-1, used in imaging scans, has not been linked to significant health risks in people. Available safety data does not report any side effects directly caused by 11C-ZTP-1, suggesting it is generally safe. However, as this is an early-stage trial, the treatment remains under careful study to ensure safety. Researchers will closely monitor participants for any side effects during and after the imaging procedures.¹²³⁴⁵

Unlike traditional imaging methods that rely on established tracers, 11C-ZTP-1 is unique because it uses a novel radioactive tracer designed to provide more precise brain imaging. Researchers are excited about this treatment because it targets specific brain receptors with potentially higher accuracy and less background noise, which could improve the clarity and reliability of brain scans. This advancement might lead to better diagnosis and understanding of brain conditions compared to current standard imaging techniques.

Research has shown that [11C]ZTP-1 effectively images a protein called PDE4B in the brain. Studies in rats and monkeys demonstrated that this tracer provides a clear signal specific to PDE4B, with minimal interference from other substances. This clarity is crucial for understanding the protein's role in inflammation and brain function. The tracer exhibited high activity and low contamination, making it promising for accurate brain imaging. These findings suggest that [11C]ZTP-1 could be a valuable tool for studying diseases related to PDE4B. In this trial, all subjects will undergo the same tests using [11C]ZTP-1 to further evaluate its imaging capabilities in healthy humans.¹²⁶⁷⁸